Follow this preprint

Cost-effectiveness of CTC guided chemo- or endocrine therapy in ER+ HER2- metastatic breast cancer – results from a randomized controlled multicenter trial

A.M.S. Berghuis, H. Koffijberg, X.G.L.V. Pouwels, F. Berger, C. Alix-Panabières, W. Jacot, J.Y. Pierga, F.C. Bidard, M.J. IJzerman
doi: https://doi.org/10.1101/2023.10.09.23296711
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Article Information

doi 
https://doi.org/10.1101/2023.10.09.23296711
History 
  • October 9, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. A.M.S. Berghuis1,11,
  2. H. Koffijberg1,
  3. X.G.L.V. Pouwels1,
  4. F. Berger2,
  5. C. Alix-Panabières3,
  6. W. Jacot4,5,6,
  7. J.Y. Pierga7,
  8. F.C. Bidard7,8 and
  9. M.J. IJzerman1,9,10,*
  1. 1Department of Health Technology and Services Research, Techmed Centre, Faculty of Behavioral, Management & Social Sciences, University of Twente, Enschede, The Netherlands
  2. 2Department of Biostatistics, Institut Curie, PSL Research University, Paris, France
  3. 3Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Center of Montpellier, Montpellier, France
  4. 4Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), France
  5. 5Translational Research Unit, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France
  6. 6INSERM, U1194, Montpellier, France
  7. 7Department of Medical Oncology, Institut Curie, Université Paris Descartes, Paris, France
  8. 8UVSQ, Paris Saclay University, Saint Cloud, France
  9. 9University of Melbourne Centre for Cancer Research, School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, Melbourne, Australia
  10. 10Erasmus School of Health Policy & Management, Erasmus University, Rotterdam, the Netherlands
  11. 11GlaxoSmithKline BV, Amersfoort, the Netherlands
  1. ↵*Correspondence: Professor Maarten IJzerman University of Melbourne Centre for Cancer Research, School of Population and Global Health maarten.ijzerman{at}unimelb.edu.au
Back to top
Posted October 09, 2023.
Download PDF
Print/Save Options
Download PDFFull Text & In-line FiguresXML

Supplementary Material

Data/Code
Email
Cost-effectiveness of CTC guided chemo- or endocrine therapy in ER+ HER2- metastatic breast cancer – results from a randomized controlled multicenter trial
A.M.S. Berghuis, H. Koffijberg, X.G.L.V. Pouwels, F. Berger, C. Alix-Panabières, W. Jacot, J.Y. Pierga, F.C. Bidard, M.J. IJzerman
medRxiv 2023.10.09.23296711; doi: https://doi.org/10.1101/2023.10.09.23296711
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area

Reviews and Context

0

Comment

0

TRIP Peer Reviews

0

Community Reviews

0

Automated Services

0

Blogs/Media

0

Author Videos

You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the medRxiv Alerts Page.

Sign In to Follow this Preprint

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.